药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

英国癌症研究院与Ideaya联合开发PARG抑制剂

2018-03-14 MedSci MedSci原创

英国癌症研究院与Ideaya联合PARG抑制剂
关注

英国癌症研究公司正与美国生物技术公司Ideaya Biosciences合作开发多聚（ADP-核糖）水解酶（PARG）的小分子抑制剂。PARG是分解多聚（ADP-核糖）的细胞酶，调节DNA修复所需的蛋白质功能。高活性PARP抑制癌细胞中的PARG，耗尽细胞内的NAD，这是细胞呼吸的一个重要因素，导致ATP("能量")的"急剧下降"，最终导致癌症细胞死亡。"英国曼彻斯特大学癌症研究中心的药物发现小组


英国癌症研究公司正与美国生物技术公司Ideaya Biosciences合作开发多聚（ADP-核糖）水解酶（PARG）的小分子抑制剂。

PARG是分解多聚（ADP-核糖）的细胞酶，调节DNA修复所需的蛋白质功能。

高活性PARP抑制癌细胞中的PARG，耗尽细胞内的NAD，这是细胞呼吸的一个重要因素，导致ATP("能量")的"急剧下降"，最终导致癌症细胞死亡。

"英国曼彻斯特大学癌症研究中心的药物发现小组很高兴能与Ideaya一起合作，进一步开发我们的PARG抑制剂计划，"药物发现小组的化学负责人Allan Jordan说。

"从我们自己的研究所取得的基础生物学发现来看，PARG抑制剂为癌细胞生存和抵抗治疗提供了一种新的途径。我们相信这些药物将为抗癌的患者提供一种真正新颖且具有临床意义的治疗方法。"

英国癌症研究所研究与创新执行总监Iain Foulkes补充道，这次合作"将加速我们重大药物的发现与转化。

Ideaya和英国癌症研究机构表示，PARG计划的数据将在今年晚些时候在美国癌症研究协会年会上公布。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851664, encodeId=0c511851664cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 28 11:47:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514183, encodeId=afdf151418374, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Mar 16 12:47:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296257, encodeId=4eff29625ef3, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Mar 14 22:46:37 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296238, encodeId=e49e29623858, content=好好努力.继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Mar 14 21:58:31 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-05-28 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851664, encodeId=0c511851664cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 28 11:47:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514183, encodeId=afdf151418374, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Mar 16 12:47:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296257, encodeId=4eff29625ef3, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Mar 14 22:46:37 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296238, encodeId=e49e29623858, content=好好努力.继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Mar 14 21:58:31 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-03-16 小华子

    #癌症研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851664, encodeId=0c511851664cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 28 11:47:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514183, encodeId=afdf151418374, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Mar 16 12:47:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296257, encodeId=4eff29625ef3, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Mar 14 22:46:37 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296238, encodeId=e49e29623858, content=好好努力.继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Mar 14 21:58:31 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-03-14 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851664, encodeId=0c511851664cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon May 28 11:47:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514183, encodeId=afdf151418374, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Fri Mar 16 12:47:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296257, encodeId=4eff29625ef3, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Mar 14 22:46:37 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296238, encodeId=e49e29623858, content=好好努力.继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Mar 14 21:58:31 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-03-14 忠诚向上

    好好努力.继续学习

    0